FDA approves 1st rapid-acting insulin
Hosted on MSN10mon
Senators demand answers from drugmaker about discontinuation of popular insulin LevemirThree U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding ... to discontinue Levemir, a long-acting insulin, "failed to take ...
Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
An FDA advisory committee mostly agreed on Friday that an investigational once-weekly insulin product carries too much risk for use in adult patients with type 1 diabetes to recommend approval in ...
Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand ...
The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin ... safe and effective alternatives to brand name drugs approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback